Claims Listing

1 to 15 (Cancelled).

16. (New) A compound of Formula I:



I

wherein:

R^1 is –CN or $–CONR^4R^5$;

R^2 is C_1-C_4 alkyl, C_3-C_6 cycloalkyl, C_3-C_6 heterocycloalkyl, C_6-C_{14} aryl, or a group of the formula:



,  or Het;

R^{3a}, R^{3b}, R^{3c}, R^{3d} and R^{3e} are each independently H, C_1-C_4 alkyl, C_1-C_4 alkoxy, $–(CH_2)_dOH$, halo, trifluoromethyl, cyano, $–(CH_2)_dNR^6R^7$, $–CO(C_1$-C_4 alkyl), $–OCO(C_1$-C_4 alkyl), $–CH(OH)(C_1$-C_4 alkyl), $–C(OH)(C_1$-C_4 alkyl$)_2$, $–SO_2NH_2$, $–(CH_2)_dCONR^8R^9$ or $–(CH_2)_dCOO(C_1$-C_4 alkyl);

R^4, R^5, R^6, R^7, R^8 and R^9 are each independently H or C_1-C_4 alkyl;

Het is pyridyl, pyrazinyl or thienyl;

a is 1, 2, 3 or 4;

b is 1, 2 or 3;

c is 1, 2 or 3;

d is 0, 1 or 2; and

X^1 and X^2 are each independently CH_2 or O;

or a pharmaceutically acceptable salt or solvate thereof.

17. (New) A compound according to claim 16 wherein:

R^4 is H and R^5 is C_1-C_4 alkyl.

18. (New) A compound according to claim 16 wherein:

R^4 is C_1-C_4 alkyl and R^5 is H.

19. (New) A compound according to claim 16 wherein:

R^2 is C_3-C_6 cycloalkyl, C_3-C_6 heterocycloalkyl or C_6-C_{14} aryl.

20. (New) A compound of Formula II:



II

wherein:

R^{10} is a group of the formula:



,  , or Het;

R^{11} and R^{12} are each independently H or C_1-C_4 alkyl, with the proviso that R^{11} and R^{12} are not both H;

R^{13a}, R^{13b}, R^{13c}, R^{13d}, and R^{13e} are each independently H, C_1-C_4 alkyl, C_1-C_4 alkoxy, $-(CH_2)_gOH$, halo, trifluoromethyl, cyano, $-(CH_2)_gNR^{14}R^{15}$, $-CO(C_1$-C_4 alkyl), $-OCO(C_1$-C_4 alkyl), $-CH(OH)(C_1$-C_4 alkyl), $-C(OH)(C_1$-C_4 alkyl$)_2$, $-SO_2NH_2$, $-(CH_2)_gCONR^{16}R^{17}$ or $-(CH_2)_gCOO(C_1$-C_4 alkyl);

R^{14}, R^{15}, R^{16} and R^{17} are each independently H or C_1-C_4 alkyl;

Het is pyridyl, pyrazinyl or thienyl;

e is 1, 2 or 3;

f is 1, 2 or 3;

g is 0, 1 or 2; and

X^3 and X^4 are each independently CH_2 or O;

or a pharmaceutically acceptable salt or solvate thereof.

21. (New) A compound according to claim 20 wherein:

R^{10} is a group of the formula:



;

X^3 is O; and

X^4 is CH_2.

22. (New) A compound according to claim 20 wherein:

R^{10} is a group of the formula:



;

X^3 is CH_2; and

X^4 is O.

23. (New) A compound according to claim 20 wherein:

R^{11} is C_1-C_4 alkyl;and

R^{12} is H.

24. (New) A compound according to claim 20 wherein:

R^{11} is H;and

R^{12} is C_1-C_4 alkyl.

25. (New) A compound according to claim 20 wherein:

R^{13a}, R^{13b}, R^{13c}, R^{13d}, and R^{13e} are each independently H, C_1-C_4 alkyl, C_1-C_4 alkoxy, $-(CH_2)_gOH$, halo, trifluoromethyl, cyano, $-CO(C_1$-C_4 alkyl), $-OCO(C_1$-C_4 alkyl), $-CH(OH)(C_1$-C_4 alkyl),
$-SO_2NH_2$ or $-(CH_2)_gCOO(C_1$-C_4 alkyl).

26. (New) A compound according to claim 20 wherein:

R^{13a}, R^{13b}, R^{13c}, R^{13d}, and R^{13e} are each independently H, C_1-C_4 alkyl, C_1-C_4 alkoxy, halo, trifluoromethyl, cyano, $-CO(C_1$-C_4 alkyl), $-OCO(C_1$-C_4 alkyl) or $-CH(OH)(C_1$-C_4 alkyl).

27. (New) A compound selected from:



,


,


,


,



,


and


,

or a pharmaceutically acceptable salt or solvate thereof.

28. (New) A composition comprising a compound according to any one of claims 16, 20 or 27 and at least one additional therapeutic agent chosen from nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV integrase inhibitors, HIV fusion inhibitors, immune modulators, CCR5 antagonists, and antiinfectives.

29. (New) A composition according to claim 28 wherein said at least one additional therapeutic agent is chosen from nelfinavir, ritonavir, lopinavir, kaletra, efavirenz, nevirapine, lamivudine, zidovudine, and tenofovir.